B
Beijing Yunshida Medical Investment Management
Incinta is an assisted reproductive health service provider
About Beijing Yunshida Medical Investment Management
Incinta Medical Holding Limited operates as a global reproductive medical company, positioning itself within the expansive and growing fertility services market. The firm is fundamentally a network of state-of-the-art fertility treatment centers, with a presence in the United States, Cambodia, and Russia. Its core business revolves around providing advanced fertility treatments to a global clientele, with a notable focus on facilitating services for overseas Chinese medical tourists.
The company's service portfolio is comprehensive, specializing in several advanced reproductive technologies. These include Natural Cycle IVF (NC-IVF), Minimal Stimulation IVF (MS-IVF), and modified conventional IVF. Beyond these, their offerings extend to in vitro fertilization, egg freezing, embryo freezing and transfer, and intrauterine insemination, catering to a wide spectrum of patient needs. This business model is driven by direct patient service fees for the various high-quality fertility treatments provided. To mitigate the financial burden on patients, the company collaborates with external financial institutions, such as CapexMD, to offer financing options, although it does not act as a direct lender.
A key strategic element for Incinta has been forming partnerships to broaden its market reach. In February 2020, the company entered into a Memorandum of Understanding (MOU) with Voycare, a company specializing in assisting overseas patients. This collaboration was designed for mutual benefit, covering marketing support, business development, and the exploration of new investment opportunities. The agreement aimed to leverage Voycare's marketing assets to tap deeper into China's IVF market, while Voycare would gain access to Incinta's international network of high-success-rate fertility clinics. For instance, its Phnom Penh clinic alone managed over 1,000 patient treatments in 2019, with plans to open new centers in Los Angeles and Moscow in 2020.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 17.7/100
- Industry
- Health
- Sector
- Fertility, Hard Tech
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Apr 2025 | $35M | $140M | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Jun 2019 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Beijing Yunshida Medical Investment Management is 440 monthly website visits, down 44.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Yunshida Medical Investment Management in its local ecosystem
The Beijing Yunshida Medical Investment Management office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Yunshida Medical Investment Management on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Yunshida Medical Investment Management’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










